Introduction {#S1}
============

Subarachnoid hemorrhage (SAH) is a devastating cerebral event, most frequently caused by an aneurysmal rupture ([@B36]). Although SAH is a cerebrovascular pathology first and foremost, it also inflicts significant damage to peripheral organs, including the heart and vascular system ([@B4]). These peripheral manifestations are clinically significant, as perturbations in cardiac output and vascular resistance may exacerbate neurological injury and increase mortality ([@B44]; [@B35]): thus, mitigating cardiac injury and effectively manipulating blood pressure are key aspects of SAH therapy. Remarkably, blood pressure management in SAH is a particularly understudied field and consequently, current clinical guidelines ([@B5]) are primarily based on small studies, rather than solid, large-cohort evidence ([@B8]). Trials testing blood pressure management regimes have not been undertaken, in part, due to the complexity of the task: many molecular mechanisms contribute to blood pressure control, both at the level of the heart and the microcirculation, but their relative contributions in the perturbed state of SAH have not been adequately defined. This makes the safe and reliable manipulation of blood pressure difficult in a patient that is particularly vulnerable.

Sympathetic activity and circulating catecholamines are rapidly and persistently elevated in SAH ([@B3]; [@B29]), forming an intuitive link between the primary injury within the brain and organ injury at remote sites. At the level of the heart, the most frequent neurocardiogenic manifestation in SAH is "stunned myocardium," a transient deficiency in left ventricular function arising from excessive catecholamine stimulation ([@B41]; [@B12]); in a small subset of patients, a more severe form of catecholamine toxicity materializes as a transient ballooning of the left ventricular apex (takotsubo cardiomyopathy) ([@B12]).

Even in the presence of a pathological reduction in cardiac output, elevated blood pressure remains an inescapable clinical feature of SAH ([@B33]). Blood pressure in SAH patients typically follows a biphasic course: initially, there is a rapid rise (within 2 days) that plateaus for 3--6 days; a proportion of patients then subsequently experience a spontaneous secondary increase in blood pressure that strongly associates with the secondary delayed ischemia and poorer neurological outcome ([@B6]; [@B7]). The immediate rise in blood pressure is almost certainly attributable to the elevated circulating catecholamines and sympathetic activity; however, the secondary hypertension that arises later is not associated with an additional elevation in catecholamine levels ([@B29]; [@B7]): this indicates that a distinct vascular mechanism drives this rise in blood pressure.

The myogenic response is a critical autoregulatory mechanism that prominently contributes to the control of vascular tone and hence, peripheral resistance ([@B19]). Although myogenic vasoconstriction is an agonist-independent, mechanosensitive response to transmural pressure, it plays a remarkably important role in amplifying pressor responses ([@B27], [@B28]). In fact, myogenic amplification is a larger contributor to the overall blood pressure response (\>60%) than the actual stimulus itself ([@B27]). Intriguingly, adrenergic signaling has the capability to feed forward and augment myogenic mechanisms ([@B25]; [@B32]): thus, sustained catecholamine stimulation may initiate a positive feedback loop that further enhances vasoconstriction in the absence of additional increases in circulating catecholamine levels. This mechanism putatively underlies the secondary, catecholamine-independent increase in blood pressure observed in SAH patients ([@B29]; [@B7]).

This investigation, therefore, assessed skeletal muscle resistance artery myogenic vasoconstriction in a mouse model of SAH. We selected skeletal muscle resistance arteries for this study, because this vascular bed represents the body's largest circulatory network (40% of body mass is skeletal muscle) and consequently, myogenic tone in these arteries is a prominent determinant of total peripheral resistance ([@B14]).

Materials and Methods {#S2}
=====================

This investigation conforms to the National Research Council's 2011 *Guide for the Care and Use of Laboratory Animals* (ISBN: 0-309-15400-6). All animal care and experimental protocols were approved by the Institutional Animal Care and Use Committee at the University of Toronto and were conducted in accordance with national animal protection laws.

Mice {#S2.SS1}
----

Wild-type mice (C57BL/6N) were purchased from Charles River Laboratories (Montreal, QC, Canada); germ-line tumor necrosis factor (TNF) alpha knockout mice (TNF^--/--^) were purchased from Taconic laboratories (Hudson, NY, United States). Inducible, smooth muscle cell-targeted TNF knockout mice, generated by crossing floxed TNF mice ([@B9]) with mice expressing a recombinant Cre recombinase under the control of a smooth muscle promoter (SMMHC-CreER^T2^) ([@B40]), have been described and utilized in our previous studies ([@B42]). Similarly, smooth muscle cell-targeted Gq~11~ knockout mice were generated by crossing floxed Gq~11~ (Gna11) mice ([@B38]) with SMMHC-CreER^T2^ mice ([@B40]) and have been described previously ([@B1]). All mice were housed in a controlled climate (21°C, 40--60% humidity) with a standard 14 h:10 h light--dark cycle, fed normal chow and had access to water and food *ad libitum*. All surgical procedures and parameter assessments were conducted during the normal work day, which coincided with the lights-on phase in the light-dark cycle.

Induction of Subarachnoid Hemorrhage {#S2.SS2}
------------------------------------

We used a well-characterized model of experimental SAH ([@B42]). Briefly, each mouse was anesthetized (isoflurane) and its head was fixed in a stereotactic frame. A 7 mm incision was made along the midline of the anterior scalp and a 0.9 mm hole drilled into the skull 4.5 mm anterior to the bregma. A spinal needle was advanced to the chiasmatic cistern: 80 μl of arterial blood from an immunologically compatible, syngeneic donor mouse was injected into the intracranial space over 10 s. The injected blood was obtained from a separate wild-type donor mouse, via cardiac puncture, immediately prior to injection and did not contain anticoagulants. Sham-operated animals underwent an identical procedure, with sterile saline injected instead of blood. Following injection, the scalp incision was closed. Sham and SAH mice received buprenorphine (0.05 mg/kg s.c. twice daily for 2 days), with the first dose administered intra-operatively. All experimental measurements were conducted at 2-days post-SAH induction or sham procedure.

Isolation and Functional Assessment of Resistance Arteries {#S2.SS3}
----------------------------------------------------------

Mouse cremaster skeletal muscle resistance arteries were dissected from the cremaster muscle, cannulated onto micropipettes, stretched to their *in vivo* lengths and pressurized to 60 mmHg, as previously described ([@B15]). Mouse olfactory cerebral arteries (a first branch of the anterior cerebral artery) were dissected, cannulated and pressurized to 45 mmHg, as previously described ([@B42]). Cremaster and cerebral arteries were imaged with a CCD camera at 40x magnification during myography measurements, with luminal diameter measured using a Crescent Electronics (Windsor, ON, Canada) video edge detector and logged using Photon Technology International FeliX32 analysis software (Horiba Canada, Inc., London, ON, Canada). Myography experiments were conducted in calcium-containing 3-morpholinopropanesulfonic acid (MOPS) buffered saline at 37°C with no perfusion (\[mmol/L\]: NaCl 147.0, KCl 4.7, CaCl~2~ 1.5, MgSO~4~ 1.2, NaH~2~PO~4~ 1.2, pyruvate 2.0, EDTA 0.02, MOPS 3.0, and glucose 5.0). Vasomotor responses to 10 μmol/L phenylephrine provided an assessment of vessel viability at the beginning of each experiment. Cremaster and cerebral arteries were required to achieve 60 and 30% constriction in response to phenylephrine, respectively: this level approximates 75% of the mean constriction stimulated by 10 μmol/L phenylephrine in the respective artery types.

Myogenic responses were elicited by stepwise 20 mmHg increases in transmural pressure from 20 to 80 mmHg (olfactory arteries) or 100 mmHg (cremaster skeletal muscle resistance arteries). At each pressure step, vessel diameter (dia~active~) was measured once a steady state was reached. Following completion of all dia~active~ measurements, the MOPS buffer was replaced with a Ca^2+^-free version and maximal passive diameter (dia~max~) was recorded at each pressure step.

Calcium sensitivity (i.e., the relationship between microvascular tone and intracellular calcium levels) was assessed by increasing extracellular calcium from 0 to 2 mmol/L under depolarizing conditions; depolarization permits the equilibration of intra- and extra-cellular cellular calcium levels, via the opening of L-type calcium channels. To maintain osmolarity, the NaCl content in the MOPS-buffered saline was reduced to compensate for the changes in osmolarity induced by the altered KCl and CaCl~2~ concentrations. The calcium-free version of this solution is formulated as \[mmol/L\]: NaCl 26.5, KCl 125.0, MgSO~4~ 1.2, NaH~2~PO~4~ 1.2, pyruvate 2.0, EDTA 1.0, MOPS 3.0, and glucose 5.0. As calcium was added to this solution, NaCl was reduced proportional to the osmotic load of the added calcium (i.e., 1.5 mmol/L of NaCl for 1 mmol/L CaCl~2~).

Myogenic tone was calculated as the percent constriction in relation to the maximal diameter at each respective transmural pressure: tone (% of dia~max~) = \[(dia~max~-dia~active~)/dia~max~\]x100, where dia~active~ is the vessel diameter in MOPS containing Ca^2+^ and dia~max~ is the diameter in Ca^2+^-free MOPS. Analyses of vasomotor responses to phenylephrine and calcium sensitivity used the same calculation, only in this case, dia~active~ represents the vessel diameter at steady state following application of the given agent.

Echocardiography {#S2.SS4}
----------------

B-mode echocardiographic measurements were collected with a 30 MHz mechanical sector transducer (Vevo 770; Visual Sonics, Toronto, ON, Canada). Systolic and diastolic volumes were calculated using the *area-length single plane* method and were calculated as 8A^2^/3πL, where A is the area of the left ventricle when viewed in B-mode parasternal long axis mode, and L is the length of the left ventricle from the apex to the aortic valve ([@B34]). In subset of experiments, measurements were collected in conjunction with the mean arterial pressure (MAP) measurements, using a Millar SPR-671 micro-tip mouse pressure catheter (Inter V Medical, Inc., Montreal, QC, Canada). Stroke volume (SV), cardiac output (CO), and total peripheral resistance (TPR) were calculated as: SV = diastolic volume -- systolic volume; CO = SV x HR; and TPR = MAP/CO.

Telemetric Blood Pressure Measurement {#S2.SS5}
-------------------------------------

Continuous MAP measurements were telemetrically collected with a PhysioTel PA-C10 Pressure Transmitter for Mice and Data Exchange Matrix (Data Sciences International, Saint Paul, MN, United States), as previously described ([@B15]). Briefly, a gel filled catheter, attached to the telemetric blood pressure transducer, was surgically inserted into the right common carotid artery and secured with a silk suture; the transducer was implanted in a subcutaneous pouch on the chest. Mice recovered from the surgical procedure for 7 days prior to collecting baseline measurements.

ELISA {#S2.SS6}
-----

Plasma epinephrine and norepinephrine levels were measured by ELISA, according to the manufacturer's instructions (Abnova cat\# KA1877; distributed by Cedarlane Laboratories, Burlington, ON, Canada).

Data Collection and Statistics {#S2.SS7}
------------------------------

A total of 413 mice were used in the present study; only male mice were utilized, as this was a necessary prerequisite for both the experimental model (i.e., cremaster arteries) and smooth muscle cell-targeted gene deletion. Mice were randomized into groups, including treatment interventions, prior to the Sham/SAH surgical procedures; there was no mortality associated with the SAH surgery. Data collection did not require blinding.

All data are expressed as means ± standard error of the mean (SEM), where n is the number of independent measures. Using data from our previous studies ([@B26]; [@B42]; [@B15]), we calculated the experimental group sizes required to provide an 80% power level for the detection of the anticipated differences between groups, with a two-tailed alpha level of 0.05. Data were statistically analyzed using GraphPad Prism 8 software (San Diego, CA, United States) using a Shapiro--Wilk normalicy test and parametric comparisons. Specifically, a Student's *t*-test was utilized for the comparison of two independent groups; for comparison of multiple independent groups, an ANOVA was utilized, followed by a Dunnett's *post hoc* test. For the comparison of myogenic responses, calcium sensitivity and dose--response relationships, data were analyzed with a two-way ANOVA, followed by a Tukey's *post hoc* test. In one instance (plasma norepinephrine levels), data were not normally distributed: in this case, a non-parametric Mann--Whitney test was utilized for the statistical comparison; this is noted in the legend. Differences were considered significant at *P* \< 0.05.

Results {#S3}
=======

Experimental Subarachnoid Hemorrhage Induces a Cardiovascular Phenotype {#S3.SS1}
-----------------------------------------------------------------------

At 2-days post-induction, experimental SAH emulates several key peripheral cardiovascular characteristics that are observed clinically, including elevated circulating epinephrine levels ([Figure 1A](#F1){ref-type="fig"}), reduced cardiac output ([Figure 1B](#F1){ref-type="fig"}) and elevated total peripheral resistance ([Figure 1C](#F1){ref-type="fig"}). A summary of the measured echocardiographic parameters can be found in [Supplementary Table 1](#PS1){ref-type="supplementary-material"}. Although plasma epinephrine levels are elevated, circulating norepinephrine levels are not affected ([Supplementary Figure 1](#PS1){ref-type="supplementary-material"}). Surprisingly, SAH does not increase MAP at 2-days post-SAH induction (measured under anesthesia; sham = 73 ± 2 mmHg, *n* = 13; SAH = 71 ± 2 mmHg, *n* = 12; P = N.S. by Student's *t*-test). Consistent with these measures, telemetric blood pressure measurements in conscious mice indicate that SAH does not appreciably alter MAP within 1-week post-SAH induction ([Supplementary Figure 2](#PS1){ref-type="supplementary-material"}).

![Subarachnoid hemorrhage (SAH) induces a cardiovascular phenotype. At 2-days post-SAH induction, **(A)** plasma epinephrine levels are elevated (sham *n* = 8, SAH *n* = 10), **(B)** cardiac output is reduced (sham *n* = 35, SAH *n* = 35) and **(C)** total peripheral resistance is elevated (sham *n* = 7, SAH *n* = 8). **(D)** The elevated peripheral resistance correlates with augmented cremaster skeletal muscle resistance artery myogenic tone (sham dia~max~: 78 ± 2 μm, *n* = 26; SAH 78 ± 2 μm, *n* = 22). **(E)** Phenylephrine-stimulated vasoconstriction is also greater in cremaster arteries isolated from SAH mice (sham dia~max~: 78 ± 2 μm, *n* = 26; SAH 78 ± 2 μm, *n* = 22); however, **(F)** calcium sensitivity is unaffected (sham dia~max~: 72 ± 5 μm, *n* = 7; SAH dia~max~: 80 ± 3 μm, *n* = 8). \**P* \< 0.05.](fphys-11-00402-g001){#F1}

At the level of microvascular function, the elevation in total peripheral resistance correlates with augmented cremaster skeletal muscle resistance artery myogenic reactivity ([Figure 1D](#F1){ref-type="fig"}). Representative diameter tracings from vessels isolated from sham and SAH mice are displayed in [Supplementary Figure 3](#PS1){ref-type="supplementary-material"}. Phenylephrine-stimulated vasoconstriction is also greater in arteries isolated from SAH mice ([Figure 1E](#F1){ref-type="fig"}); however, the upward shift is entirely due to SAH's effect on myogenic reactivity, which increases basal tone. When baseline tone is normalized, phenylephrine responses in arteries isolated from sham and SAH mice are virtually identical ([Supplementary Figure 4](#PS1){ref-type="supplementary-material"}). Neither calcium sensitivity (i.e., constriction induced by raising intracellular calcium levels; [Figure 1F](#F1){ref-type="fig"}) nor maximal luminal diameter at 60 mmHg under calcium-free conditions (sham = 78 ± 2 μm, *n* = 26; SAH = 78 ± 2 μm, *n* = 22; P = N.S. by Student's *t*-test) are affected by SAH. Taken together, the vascular phenotype appears to be specific to the myogenic mechanism.

β-Adrenergic Receptor Blockade Selectively Normalizes Cardiac Function in Subarachnoid Hemorrhage {#S3.SS2}
-------------------------------------------------------------------------------------------------

β-Adrenergic receptor blockade is an effective means to prevent catecholamine-induced cardiac injury ([@B22]). In mice with SAH, the β~1~-adrenergic receptor antagonist bisoprolol (mice treated twice daily for 2 days with i.p. injections; 10 mg/kg initial pre-operative dose followed by 5 mg/kg for all subsequent injections) successfully protects cardiac function ([Figure 2A](#F2){ref-type="fig"}); a summary of the measured echocardiographic parameters for bisoprolol-treated SAH mice can be found in [Supplementary Table 2](#PS1){ref-type="supplementary-material"}. Notably, bisoprolol treatment is only effective when delivered pre-operatively, as we did not observe a protective effect in preliminary experiments when bisoprolol was delivered immediately following the SAH induction surgery ([Supplementary Figure 5](#PS1){ref-type="supplementary-material"}). This latter finding indicates that: (i) the majority of cardiac injury must occur in the acute phase of SAH, when the catecholamine surge is presumably highest; and (ii) β-blockade can prevent, but not reverse, cardiac dysfunction in SAH. In contrast to its cardioprotective effect, bisoprolol treatment does not prevent the SAH-induced augmentation of cremaster skeletal muscle resistance artery myogenic reactivity ([Figure 2B](#F2){ref-type="fig"}); bisoprolol does not affect phenylephrine responses ([Figure 2C](#F2){ref-type="fig"}) and has no effect in sham mice ([Supplementary Figure 6](#PS1){ref-type="supplementary-material"}). Consistent with these *in vivo* data, *in vitro* bisoprolol treatment (5 μmol/L, 30 min) does not affect myogenic reactivity or phenylephrine responses in cremaster skeletal muscle resistance arteries isolated from naïve mice ([Supplementary Figure 7](#PS1){ref-type="supplementary-material"}).

![β-Adrenergic signaling drives the cardiac phenotype in SAH, but not the vascular phenotype. **(A)** Bisoprolol (Bis; twice daily for 2 days with i.p. injections; 10 mg/kg initial pre-operative dose followed by 5 mg/kg for all subsequent injections) prevents the compromised cardiac function observed at 2-days post-SAH induction (sham *n* = 12, SAH *n* = 11, SAH + Bis *n* = 10). **(B)** However, bisoprolol treatment does not prevent the augmentation of myogenic reactivity in cremaster skeletal muscle resistance arteries isolated from SAH mice, nor **(C)** does it alter vasoconstriction in response to phenylephrine (sham dia~max~: 80 ± 2 μm, *n* = 13; SAH dia~max~: 80 ± 2 μm, *n* = 10; SAH + Bis dia~max~: 76 ± 2 μm, *n* = 7). **(D)** In naïve mice, the β-adrenergic receptor agonist isoproterenol (150 mg/kg i.p. for 2 days) reduces cardiac output (control *n* = 5, Isoproterenol *n* = 9). However, in contrast to SAH, both **(E)** myogenic reactivity and **(F)** phenylephrine responses in cremaster skeletal muscle resistance arteries isolated from isoproterenol-treated mice are attenuated (control dia~max~: 80 ± 4 μm, *n* = 8; isoproterenol dia~max~: 79 ± 2 μm, *n* = 8). \**P* \< 0.05.](fphys-11-00402-g002){#F2}

We next treated naïve mice with the β-adrenergic receptor agonist isoproterenol, to determine to what extent selective β-adrenergic receptor activation recapitulates the SAH phenotype. Consistent with our conclusion that β-adrenergic receptors mediate cardiac injury in SAH, isoproterenol (150 mg/kg/day i.p. for 2 days) reduces cardiac output ([Figure 2D](#F2){ref-type="fig"}); a full summary of the measured cardiac and systemic hemodynamic parameters in isoproterenol-treated mice can be found in [Supplementary Table 3](#PS1){ref-type="supplementary-material"}. Surprisingly, cremaster skeletal muscle resistance artery myogenic reactivity ([Figure 2E](#F2){ref-type="fig"}) and phenylephrine responses ([Figure 2F](#F2){ref-type="fig"}) are both reduced following *in vivo* isoproterenol treatment. In the latter case, the reduced phenylephrine responses are primarily due to a shift in basal myogenic tone: when basal tone is accounted for, phenylephrine responses are not different ([Supplementary Figure 8](#PS1){ref-type="supplementary-material"}). *In vitro*, isoproterenol (1 μmol/L, 30 min) reproduces the *in vivo* treatment phenotype: reduced myogenic reactivity and phenylephrine responses, with the latter due to reduced myogenic/basal tone ([Supplementary Figure 9](#PS1){ref-type="supplementary-material"}).

α-Adrenergic Receptor Blockade Selectively Normalizes Vascular Function in Subarachnoid Hemorrhage {#S3.SS3}
--------------------------------------------------------------------------------------------------

As expected, the α~1~-adrenergic receptor antagonist terazosin (mice treated twice daily for 2 days with i.p. injections; 1 mg/kg initial pre-operative dose followed by 0.5 mg/kg for all subsequent injections) does not prevent cardiac dysfunction in mice with SAH ([Figure 3A](#F3){ref-type="fig"}). A summary of the measured echocardiographic parameters for terazosin-treated SAH mice can be found in [Supplementary Table 4](#PS1){ref-type="supplementary-material"}. Although terazosin is not cardioprotective, it successfully prevents the SAH-induced augmentation of cremaster skeletal muscle resistance artery myogenic reactivity ([Figure 3B](#F3){ref-type="fig"}). In this experimental cohort, phenylephrine responses were statistically higher in arteries isolated from SAH mice, compared to those isolated from sham-operated controls ([Figure 3C](#F3){ref-type="fig"}). The augmented phenylephrine responses are primarily due to a shift in basal tone, as baseline normalization eliminates the difference between the groups ([Supplementary Figure 10](#PS1){ref-type="supplementary-material"}). This baseline shift is not observed in arteries isolated from terazosin-treated SAH mice and therefore, phenylephrine responses appear normalized in arteries isolated from terazosin-treated SAH mice ([Figure 3C](#F3){ref-type="fig"}). Of note, terazosin also normalizes myogenic reactivity when administered post-SAH induction ([Supplementary Figure 11](#PS1){ref-type="supplementary-material"}) and therefore, potentially represents a viable treatment option.

![α-Adrenergic signaling drives the vascular phenotype in SAH, but not the cardiac phenotype. **(A)** Terazosin (TZ; twice daily for 2 days with i.p. injections; 1 mg/kg initial pre-operative dose followed by 0.5 mg/kg for all subsequent injections) has no effect on the compromised cardiac function observed at 2-days post-SAH induction (sham *n* = 16, SAH *n* = 16, SAH + TZ *n* = 12). **(B)** However, terazosin treatment successfully normalizes the augmented myogenic reactivity in cremaster skeletal muscle arteries isolated from SAH mice. **(C)** Phenylephrine responses are enhanced in cremaster arteries isolated from SAH mice; this augmentation is also normalized by terazosin treatment (sham dia~max~: 76 ± 3 μm, *n* = 13; SAH dia~max~: 76 ± 3 μm, *n* = 12; SAH + TZ dia~max~: 74 ± 2 μm, *n* = 13). **(D)** Calcium sensitivity is not altered by terazosin treatment (SAH dia~max~: 80 ± 3 μm, *n* = 8; SAH + TZ dia~max~: 78 ± 4 μm, *n* = 7). The SAH curve in **(D)** is reproduced from [Figure 1E](#F1){ref-type="fig"} for comparison to the SAH + TZ curve. \**P* \< 0.05.](fphys-11-00402-g003){#F3}

As predicted by our [Figure 1](#F1){ref-type="fig"} data, calcium sensitivity in arteries isolated from terazosin-treated SAH mice is not different from that found in arteries isolated from SAH mice ([Figure 3D](#F3){ref-type="fig"}). Intriguingly, terazosin treatment had a markedly different effect in sham mice, where it augmented myogenic tone ([Supplementary Figure 12](#PS1){ref-type="supplementary-material"}). *In vitro*, terazosin (25 nmol/L, 30 min) has no effect on myogenic reactivity in cremaster skeletal muscle resistance arteries isolated from naïve mice ([Supplementary Figure 13A](#PS1){ref-type="supplementary-material"}). As expected, this treatment induces a clear rightward shift in the phenylephrine dose-response relationship ([Supplementary Figure 13B](#PS1){ref-type="supplementary-material"}; log EC~50~ values for phenylephrine-stimulated vasoconstriction: control = −6.07 ± 0.20, *n* = 6; control + terazosin = −4.91 ± 0.07, *n* = 6; *P* \< 0.05 by paired Student's *t*-test).

We attempted to replicate the SAH vascular phenotype, by treating cremaster skeletal muscle resistance arteries isolated from naïve mice with phenylephrine *in vitro*. Our preliminary experiments indicated that a relatively long incubation period is required to observe an effect on myogenic tone (*data not shown*). Consistent with our expectations, naïve arteries treated with 1 μmol/L phenylephrine for 4 h display higher myogenic tone than control arteries ([Figure 4A](#F4){ref-type="fig"}); the treatment does not alter phenylephrine-simulated vasoconstriction ([Figure 4B](#F4){ref-type="fig"}). However, in contrast to our sham/SAH data ([Figure 1F](#F1){ref-type="fig"}), calcium sensitivity is higher in phenylephrine-treated arteries, relative to control arteries ([Figure 4C](#F4){ref-type="fig"}). It is notable, however, that the phenylephrine-treated naïve arteries in [Figure 4C](#F4){ref-type="fig"} and the sham-operated arteries in [Figure 1F](#F1){ref-type="fig"} actually have comparable calcium sensitivity (P = N.S. for [Figure 1F](#F1){ref-type="fig"} sham versus [Figure 4C](#F4){ref-type="fig"} phenylephrine; *P* \< 0.05 for [Figure 1F](#F1){ref-type="fig"} sham versus [Figure 4C](#F4){ref-type="fig"} control by two-way ANOVA). This profile also applies to myogenic tone at the higher transmural pressures (at both 80 and 100 mmHg, P = N.S. for [Figure 1D](#F1){ref-type="fig"} sham versus [Figure 4A](#F4){ref-type="fig"} phenylephrine; *P* \< 0.05 for [Figure 1D](#F1){ref-type="fig"} sham versus [Figure 4A](#F4){ref-type="fig"} control by Student's *t*-test). Thus, it appears that the phenylephrine treatment maintains the sham level of calcium sensitivity and myogenic tone, while the absence of pro-constrictive signaling over the relatively long incubation period results in reduced calcium sensitivity and myogenic tone. To examine whether non-adrenergic pro-constrictive stimuli also increase calcium sensitivity and myogenic tone *in vitro*, we repeated our long-term incubation experiments using 10 nmol/L angiotensin II. In contrast to phenylephrine ([Figure 4](#F4){ref-type="fig"}), angiotensin II treatment fails to maintain calcium sensitivity and myogenic reactivity ([Supplementary Figure 14](#PS1){ref-type="supplementary-material"}), despite stimulating vasoconstriction when applied to cremaster arteries.

![α-Adrenergic signals augment myogenic reactivity *in vitro.* In **(A--C)**, cremaster skeletal muscle resistance arteries isolated from naïve mice were treated for 4 h with either 1 μmol/L phenylephrine or control buffer *in vitro*. The arteries were then washed and assessed in normal buffer. **(A)** Arteries treated with phenylephrine possess higher myogenic reactivity than control arteries. Although *in vitro* phenylephrine treatment **(B)** does not affect subsequent phenylephrine-stimulated vasoconstriction responses, **(C)** calcium sensitivity is increased (control dia~max~: 69 ± 2 μm, *n* = 10; phenylephrine dia~max~: 73 ± 3 μm, *n* = 9). **(D)** Phenylephrine-stimulated vasoconstriction is abolished in cremaster skeletal muscle resistance arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice \[sm-Gq11(KO); dia~max~: 96 ± 10, *n* = 6\], relative to wild-type littermate controls \[sm-Gq11(WT); dia~max~: 83 ± 6, *n* = 6\]. **(E)** In addition to eliminating phenylephrine responses, smooth muscle cell-targeted Gq~11~ gene deletion also attenuates myogenic tone \[sm-Gq11(WT) dia~max~: 83 ± 6, *n* = 6; sm-Gq11(KO) dia~max~: 88 ± 12, *n* = 4\]. \**P* \< 0.05.](fphys-11-00402-g004){#F4}

To further substantiate our conclusion that endogenous catecholamines modulate myogenic reactivity *in vivo*, we assessed myogenic reactivity in cremaster arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice. Because the loss of Gq~11~ expression abolishes many pro-constrictive signals, including α~1~-adrenergic receptor signaling, this knockout model provides a reasonable *in vivo* recapitulation of prolonged artery incubation in MOPS buffer *in vitro*. As expected, phenylephrine responses are absent in cremaster skeletal muscle resistance arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice ([Figure 4D](#F4){ref-type="fig"}). Consistent with our hypothesis, myogenic tone is strongly attenuated in arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice, relative to wild-type controls ([Figure 4E](#F4){ref-type="fig"}).

Subarachnoid Hemorrhage Augments Myogenic Reactivity by Altering Mechanosensor Function {#S3.SS4}
---------------------------------------------------------------------------------------

Collectively, our data imply that SAH augments myogenic reactivity via an upstream mechanism unique to the myogenic response, rather than by altering general contractility mechanisms that lie downstream. This aspect focused our attention on membrane-bound tumor necrosis factor (mTNF), which serves as the myogenic mechanosensor in cremaster skeletal muscle resistance arteries ([@B15]). Consistent with our hypothesis that SAH modulates mechanosensor function, SAH fails to augment myogenic tone in cremaster skeletal muscle resistance arteries isolated from both germline and smooth muscle cell-targeted TNF knockout mice ([Figure 5](#F5){ref-type="fig"}). Notably, phenylephrine treatment *in vitro* (1 μmol/L for 4 h) augments myogenic tone and calcium sensitivity in naïve cremaster skeletal muscle resistance arteries isolated from germline TNF knockout mice ([Figure 6](#F6){ref-type="fig"}): thus, the α-adrenergic receptor-dependent effects on calcium sensitivity observed in [Figure 4C](#F4){ref-type="fig"} does not explain the augmented myogenic tone in SAH. In wild-type mice, cremaster skeletal muscle resistance artery TNF mRNA expression does not increase in SAH relative to sham controls (sham = 1.00 ± 0.17 arbitrary units relative to HMBS, *n* = 5; SAH = 0.65 ± 0.21 arbitrary units, *n* = 5; P = N.S. by Student's *t-*test): this indicates that SAH most likely modulates the mechanosensitive mTNF signaling complex, rather than by solely changing TNF expression itself.

![Tumor necrosis factor (TNF) gene deletion abolishes the SAH-induced myogenic tone augmentation. In cremaster skeletal muscle resistance arteries isolated from germline tumor necrosis factor knockout mice (TNF KO), neither **(A)** myogenic tone nor **(B)** phenylephrine responses are affected by SAH (at 2-days post-SAH induction; sham dia~max~: 69 ± 4 μm, *n* = 7; SAH dia~max~: 71 ± 6 μm, *n* = 6). Accordingly, in cremaster skeletal muscle resistance arteries isolated from smooth muscle cell-targeted tumor necrosis factor knockout mice (sm-TNF KO), neither **(C)** myogenic tone (sham dia~max~: 90 ± 4, *n* = 6; SAH dia~max~: 77 ± 7, *n* = 6) nor **(D)** phenylephrine responses are affected by SAH (sham dia~max~: 90 ± 4, *n* = 6; SAH dia~max~: 72 ± 6, *n* = 7).](fphys-11-00402-g005){#F5}

![∝-adrenergic signaling augments myogenic reactivity and calcium sensitivity despite tumor necrosis factor (TNF) gene deletion. Cremaster skeletal muscle resistance arteries isolated from TNF KO mice were treated for 4 h with either 1 μmol/L phenylephrine or control buffer *in vitro*. The arteries were then washed and assessed in normal buffer. Arteries treated with phenylephrine display higher **(A)** myogenic reactivity (control dia~max~: 71 ± 4 μm, *n* = 5; phenylephrine dia~max~: 70 ± 3 μm, *n* = 6) and **(B)** calcium sensitivity (control dia~max~: 68 ± 6 μm, *n* = 5; phenylephrine dia~max~: 69 ± 4 μm, *n* = 5) than control arteries; however, the treatment does not affect **(C)** responses to phenylephrine (control dia~max~: 68 ± 6 μm, *n* = 5; phenylephrine dia~max~: 69 ± 4 μm, *n* = 5). \**P* \< 0.05.](fphys-11-00402-g006){#F6}

To add further credence to our conclusion that SAH modulates mTNF mechanosensor function, we capitalized on a key mechanistic difference between cremaster and cerebral resistance arteries: mTNF does not serve as a mechanosensor in olfactory cerebral arteries ([@B15]). Consistent with this functional difference, terazosin (mice treated twice daily for 2 days with i.p. injections; 1 mg/kg initial pre-operative dose followed by 0.5 mg/kg for all subsequent injections) fails to normalize the augmented myogenic reactivity in olfactory cerebral arteries ([Figure 7A](#F7){ref-type="fig"}) ([@B42]). Phenylephrine responses in olfactory arteries isolated from mice with SAH are not affected by *in vivo* terazosin treatment ([Figure 7B](#F7){ref-type="fig"} and [Supplementary Figure 15](#PS1){ref-type="supplementary-material"}). The log EC~50~ values for phenylephrine-stimulated vasoconstriction does not differ between the three groups (sham = −6.05 ± 0.16, *n* = 5; SAH = −6.33 ± 0.15, *n* = 5; SAH + terazosin = −6.09 ± 0.15, *n* = 6; P = N.S. by ANOVA). As expected, terazosin treatment has no effect on myogenic reactivity in olfactory cerebral arteries isolated from sham mice ([Supplementary Figure 16](#PS1){ref-type="supplementary-material"}).

![Cerebral and cremaster resistance arteries have distinct phenotypes. **(A)** Terazosin (TZ; twice daily for 2 days with i.p. injections; 1 mg/kg initial pre-operative dose followed by 0.5 mg/kg for all subsequent injections) does not normalize the augmented myogenic reactivity observed in olfactory cerebral arteries isolated from mice at 2-days post-SAH induction (sham dia~max~: 108 ± 4 μm, *n* = 6; SAH dia~max~: 104 ± 7 μm, *n* = 5; SAH + TZ dia~max~: 101 ± 9 μm, *n* = 5). **(B)** Phenylephrine responses in olfactory cerebral arteries are unaffected by SAH or terazosin treatment (sham dia~max~: 110 ± 4 μm, *n* = 5; SAH dia~max~: 104 ± 7 μm, *n* = 5; SAH + TZ dia~max~: 108 ± 10 μm, *n* = 6). **(C)** Phenylephrine-stimulated vasoconstriction is abolished in olfactory cerebral resistance arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice \[sm-Gq11(KO); dia~max~ = 156 ± 5 μm, *n* = 10\], relative to wild-type littermate controls \[sm-Gq11(WT); dia~max~ = 144 ± 5, *n* = 5\]. However, **(D)** there is no effect of the targeted Gq~11~ gene deletion on myogenic tone. \**P* \< 0.05.](fphys-11-00402-g007){#F7}

We complemented these experiments by assessing myogenic reactivity in olfactory cerebral arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice. As in cremaster arteries ([Figure 4D](#F4){ref-type="fig"}), the loss of Gq~11~ expression abolishes phenylephrine-stimulated vasoconstriction in olfactory cerebral arteries ([Figure 7C](#F7){ref-type="fig"}). However, in contrast to cremaster arteries ([Figure 4E](#F4){ref-type="fig"}), olfactory artery myogenic reactivity is not affected by the smooth muscle cell-targeted loss of Gq~11~ expression ([Figure 7D](#F7){ref-type="fig"}). This is consistent with our conclusion that α-adrenergic signaling does not modulate persistent effects on vascular tone in cerebral arteries, in contrast to skeletal muscle resistance arteries.

Discussion {#S4}
==========

Since effectively managing blood pressure is a key aspect of SAH therapy, understanding the peripheral cardiovascular effects of SAH is clinically relevant. To this end, our investigation examined the effects of elevated catecholamines on cardiac function and vascular reactivity in an experimental mouse model of SAH. We show that SAH reduces cardiac output and elevates total peripheral resistance *in vivo*; in isolated skeletal muscle resistance arteries *ex vivo*, SAH augments myogenic vasoconstriction. These cardiac and vascular effects are driven by beta- and alpha-adrenergic receptors, respectively. Therapeutically targeting adrenergic receptors in SAH patients, therefore, may possess utility in managing the peripheral effects of SAH during recovery.

Because SAH is a highly-complex pathology, there are no experimental SAH models that perfectly recapitulate all of the clinical aspects of the disease. The blood injection model utilized in the present study has several key advantages, including a relatively uniform hemorrhage/injury stimulus, low mortality and technical ease; however, the model does not simulate an aneurysmal rupture (i.e., a punctured artery) and does not fully mimic the changes in intracranial pressure that occur clinically as a result of subarachnoid bleeding ([@B16]). Further, rodents eliminate blood within the subarachnoid space much faster than humans, resulting in a species-specific time course for the pathology ([@B20]). Consequently, we ([@B42]; [@B18]) and others ([@B20]) have demonstrated that cerebrovascular dysfunction and secondary brain injury develop much more rapidly in experimental rodent models, than what is clinically observed in humans ([@B23]; [@B16]). For example, cerebral vasospasm (i.e., constriction of large cerebral arteries) occurs within hours to 5 days post-SAH in experimental models, versus 3--12 days post-SAH in patients ([@B23]; [@B16]). With this in mind, the present study set the assessment timepoint at 2-days post-SAH induction, which aligns with SAH's peak effect on myogenic tone in cerebral arteries ([@B42]) and is a key therapeutic window for intervention in the model ([@B42]; [@B18]).

To our knowledge, this study is the first to demonstrate secondary cardiac injury in a blood-injection model of SAH. Clinically, 16--30% of patients with SAH experience left ventricular dysfunction within the first 2 days of SAH ([@B2]; [@B12]). The cardiac phenotype that we observe in our experimental model, ventricular dysfunction with normal ejection fraction, occurs in approximately half of the patients that develop SAH-induced neurogenic cardiomyopathy ([@B2]). Although cardiac dysfunction in SAH is widely attributed to catecholamine toxicity ([@B41]; [@B12]), there is a distinct lack of clinical data to guide intervention: consequently, the treatment of neurocardiac injury in SAH remains largely empirical. However, catecholamine toxicity is not unique to SAH: indeed, elevated catecholamines are widely known to drive profound cardiac injury in a number of disease entities, most notably heart failure ([@B22]). In this regard, there is a wealth of clinical data demonstrating that β-blockers protect the heart against catecholamine-derived injury ([@B22]). Yet, β-blockade in SAH has yielded mixed results: while a few studies purport a beneficial, cardioprotective effect ([@B30]; [@B17]), most other retrospective studies find no concrete evidence that taking β-blockers prior to SAH protects against neurocardiac injury ([@B24]; [@B21]).

Consistent with the accepted catecholamine toxicity paradigm ([@B41]; [@B12]), cardiac dysfunction is fully prevented by the β-adrenergic receptor antagonist bisoprolol. On the surface, our data appear to contradict the negative clinical analyses; however, there are two significant confounds that likely contribute to the discrepancy: (i) patients on β-blockers prior to SAH either already have cardiac injury or are highly vulnerable to cardiac injury, rendering direct comparisons to a non-β-blocker control group difficult; and (ii) the β-blocker dosage in patients is titrated with respect to their basal sympathetic activity and may be overwhelmed by the SAH-induced catecholamine surge. Indeed, our preliminary experiments indicated that a pre-treatment approach is required for efficacy: since the catecholamine surge is highest immediately following aneurysmal rupture, it is entirely reasonable that effective treatment requires adequate β-blockade at the time of SAH. Our pre-treatment requirement provides additional insight, in that it suggests that the persistently elevated catecholamines that follow the initial surge do not maintain or substantively aggravate the cardiac dysfunction induced by the surge itself. Taken together, our data indicate that β-blockers are cardioprotective in SAH, but that the therapeutic time window is very narrow and therefore, cardioprotection may be clinically difficult to achieve.

Intuitively, persistently high sympathetic activity and circulating catecholamines must alter microvascular function; yet, no studies to date have assessed peripheral vascular function in SAH. In this investigation, we measured skeletal muscle resistance artery myogenic tone, because: (i) myogenic reactivity is a key determinant of microvascular resistance; and (ii) skeletal muscle resistance arteries form the body's largest circulatory network and therefore, prominently contribute to total peripheral resistance ([@B14]). Our myogenic tone measurements are conducted *ex vivo*, in order to eliminate the direct influences of circulating catecholamines and neuronal inputs: our control experiments demonstrating that bisoprolol and terazosin treatment *in vitro* do not impact myogenic tone effectively confirm that the target adrenergic receptors were not activated during *ex vivo* testing. Thus, the effects of SAH and *in vivo* treatments are *persistent* effects on smooth muscle cell function that remain in the absence of continuous adrenergic receptor activation.

Our data demonstrate that SAH induces a persistent augmentation of myogenic tone that correlates with elevated total peripheral resistance *in vivo*. Unlike the cardiac phenotype, this vascular phenotype is not driven by β-adrenergic signaling. Selective β-adrenergic activation *in vivo* and *in vitro* attenuates myogenic vasoconstriction, presumably by stimulating long-lasting vasodilatory mechanisms via endothelial (e.g., nitric oxide) and smooth muscle cell-dependent mechanisms ([@B10]). In cremaster skeletal muscle resistance arteries, the most abundant adrenergic receptor subtype is the α~1~-adrenergic receptor ([@B14]): consequently, pro-constrictive α-adrenergic signaling overwhelms any vasodilative β-adrenergic receptor activity in response to high catecholamine concentrations. Given its abundant receptor expression, it is entirely reasonable that α-adrenergic signaling would drive the augmented myogenic tone phenotype in SAH.

Although myogenic tone and TPR are elevated in our SAH model, the magnitude is not large enough to elicit a hypertensive phenotype. Indeed, the lack of hypertension in our model is surprising, given that it is a prevalent clinical feature of SAH ([@B33]). Since cardiomyopathy is far more prevalent in our experimental model than the 16--30% observed clinically ([@B2]; [@B12]), it is tempting to speculate that the cardiac phenotype in our experimental model effectively masks a mechanism that otherwise would elevate blood pressure in a clinical setting. Accordingly, if the microvascular phenotype is similarly prevalent in both mice and humans, then the lower incidence of cardiac dysfunction in human patients would set the stage for the broadly observed hypertensive phenotype. Translational studies, therefore, are necessary to ascertain whether this vascular phenotype is present clinically in SAH patients.

Although bisoprolol fails as an intervention unless it is used as a pre-treatment, terazosin effectively normalizes vascular reactivity when administered following SAH induction: this indicates that terazosin is more amenable for use as a clinical intervention. Should translational studies observe a catecholamine-dependent augmentation of myogenic tone in arteries derived from human SAH patients, our study predicts that (i) α~1~-adrenergic receptor antagonists may be more effective at lowering blood pressure than other routinely utilized medications and (ii) prophylactic α~1~-adrenergic antagonism in high-risk SAH patients may be an effective approach to prevent delayed secondary increases in blood pressure.

At a mechanistic level, catecholamines and synthetic adrenergic agonists are known to increase vascular smooth muscle cell calcium sensitivity (i.e., the response magnitude elicited by a given cytosolic calcium concentration) ([@B31]; [@B39]). We therefore hypothesized that SAH augments myogenic reactivity by a calcium sensitization mechanism. Consistent with this hypothesis, phenylephrine treatment *in vitro* augmented both cremaster skeletal muscle resistance artery calcium sensitivity and myogenic tone. Interestingly, this calcium-sensitizing effect is not a universal feature of all pro-constrictive G-protein coupled receptor stimuli, as *in vitro* angiotensin II treatment fails to mimic these phenylephrine effects, despite eliciting vasoconstriction.

Since calcium sensitivity appears to be maximal under sham/control settings, phenylephrine can only increase calcium sensitivity following prolonged withdrawal of the physiological inputs. To further explore this withdrawal aspect, we assessed myogenic reactivity in cremaster arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice, where α~1~-adrenergic and other pro-constrictive G-protein coupled receptor inputs would be eliminated in vascular smooth muscle cells. Consistent with our *in vitro* treatment data, myogenic tone is strongly attenuated in arteries isolated from smooth muscle cell-targeted Gq~11~ knockout mice, relative to wild-type controls. Olfactory cerebral artery myogenic tone is not affected by Gq~11~ gene deletion, indicating that Gq~11~-dependent/α-adrenergic signals likely do not modulate calcium sensitivity in all vascular beds. This variation is presumably dictated by the distinct differentiation states of the vascular smooth muscle cells within the two respective vascular beds.

Although α-adrenergic signaling is capable of modulating calcium sensitivity in cremaster skeletal muscle resistance arteries, several lines of compelling evidence indicate that this mechanism *does not* mediate the SAH-induced augmentation of myogenic tone: (i) calcium sensitivity appears to be maximal under sham conditions and does not increase in SAH; (ii) terazosin treatment in SAH mice normalizes cremaster artery myogenic tone, but does not alter calcium sensitivity; and (iii) the SAH-induced augmentation in myogenic tone is sensitive to TNF gene deletion, whereas phenylephrine-stimulated calcium sensitization *in vitro* is not. Thus, we rejected our hypothesis that SAH augments myogenic reactivity by a calcium sensitization mechanism and shifted our investigative attention away from mechanisms that modulate calcium sensitivity.

As an important caveat, we have not directly measured intracellular calcium levels in cremaster arteries with a calcium sensitive dye, due to a poor signal-to-noise ratio \[i.e., a 50% vasoconstriction in response to phenylephrine stimulates only a 5% change in the calcium-sensitive Fura-2 ratio ([@B15])\]. As a consequence, this study does not directly define the relationship between intracellular calcium and vasoconstriction. We overcame our limited ability to directly measure calcium by using a calcium ramp under depolarizing conditions, with the presumptions that (i) the opening of L-type calcium channels consistently clamps intracellular calcium in all treatment groups and (ii) the depolarizing condition itself does not obscure differences in calcium sensitivity. Thus, the conclusions drawn from our calcium sensitivity data must be viewed with appropriate caution.

We shifted our focus to TNF, a critical myogenic mechanosensor in cremaster skeletal muscle resistance arteries ([@B15]). As a mechanosensor, the full-length, membrane-bound form of TNF (mTNF) creates a mechanosensitive pair with its receptors that transmits an outside-in signal through mTNF itself. This is termed a "reverse signal," because the canonical signaling mechanism involves the cleavage-based release of a soluble TNF form that signals as a receptor ligand ([@B11]; [@B15]). In mouse cremaster arteries, acutely deleting the TNF gene or scavenging TNF with etanercept strongly attenuates myogenic responsiveness ([@B15]), suggesting that it plays a dominant role in the mechanotransduction process.

Three important aspects about mTNF mechanosensor function must be highlighted: first, not all vascular beds utilize mTNF as a mechanosensor. In cerebral arteries, for example, TNF only signals via the canonical receptor ligand mechanism ([@B43]; [@B42]; [@B15]). Second, due to the physiological importance of myogenic reactivity, a compensatory mechanosensor mechanism engages in cremaster arteries when TNF is genetically deleted. We have not precisely defined the nature of this compensatory mechanism; however, it is clear that while myogenic reactivity is restored, functions unique to TNF are not ([@B15]). In the present study, both of our TNF knockout models had ostensibly engaged this compensatory mechanism and thus, possessed myogenic tone despite the loss of mTNF signaling. Finally, acute TNF inhibiton does not completely abolish pressure-stimulated calcium elevations ([@B15]), suggesting the presence of other mechanosensitive elements. Although our previous work indicates a substantive role for mTNF in mechanotransduction, it is unlikely to be the sole contributor. Indeed, the compensatory mechanism that emerges following TNF gene deletion may reflect the upregulation of minority contributor to myogenic reactivity.

In the present study, both germline and smooth muscle cell-targeted TNF gene deletion abolishes the SAH-induced augmentation of myogenic tone. Since soluble TNF *does not* augment myogenic reactivity in cremaster arteries ([@B15]), we propose that α-adrenergic signaling in SAH enhances reverse signals that are mechanically initiated by mTNF. This conclusion is consistent with our observations that terazosin treatment fails to normalize the augmented myogenic tone in cerebral arteries that (i) do not use mTNF as a myogenic mechanosensor ([@B15]) and (ii) augment myogenic tone via the canonical soluble TNF/TNF receptor-dependent mechanism ([@B42]). Unfortunately, we are unable to mechanistically define the nature of the altered mTNF signaling for two important reasons: (i) TNF protein expression analyses are inherently difficult in cremaster arteries, because TNF is not an abundant protein and the tissue sample size is very small; and (ii) because the mTNF reverse signaling field is still in its infancy ([@B37]; [@B13]), the identities of the cofactors that mediate mTNF reverse signaling are not currently characterized. With regard to the former, since cremaster artery mRNA expression does not change in SAH, we speculate that α-adrenergic signaling changes either the expression or activity of signaling elements that co-localize with mTNF and transduce the reverse signal, rather than changing the expression of TNF itself. The latter issue is beyond the scope of the present investigation, but represents an intriguing investigative direction to follow.

In summary, cardiac injury and spontaneous secondary hypertension are clearly associated with poor clinical outcomes in SAH: this investigation provides evidence for potential cardioprotective interventions and establishes new leads with respect to the putative cause of secondary hypertension in SAH. Our study shows that clinically utilized adrenergic receptor antagonists can prevent cardiac injury and normalize vascular function. With respect to the latter, our data suggest that α-adrenergic signaling augments mTNF-dependent mechanosensor function in skeletal muscle resistance arteries: future work targeting this mechanism could uncover new and valuable therapeutic targets to manage peripheral vascular reactivity and resistance in SAH patients.
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